HIGHLIGHTS
- who: Eslam E. Abd El-Fattah from the (UNIVERSITY) have published the research: Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management, in the Journal: (JOURNAL)
- what: The results of the trial show that nintedanib has an antifibrotic and anti-inflammatory effect outside of the lungs.
- how: As HSP70 and HSP47 are potential targets for the control of liver fibrosis due to their role in the regulation of HSCs activation collagen synthesis and fibrogenesis drugs that inhibit HSP47 or induce HSP70 can be tested for their effectiveness against liver fibrosis especially . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.